Cite

HARVARD Citation

    Nørgaard, J. et al. (n.d.). P602 Vedolizumab subcutaneous influencing disease course in Constant-care app solution. Journal of Crohn's and colitis. pp. S547-S548. [Online]. 
  
Back to record